Monopar Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Monopar Therapeutics (MNPR).

Price Target Range — 10 Quarters

Analyst Consensus — 14 Analysts

12Buy

2Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$98Upside to Avg. PT+25.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 11, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$128→$145
Aug 13, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$125→$128
Aug 13, 2026	Cantor Fitzgerald	Kristen Kluska	Downgrade	Overweight→Neutral	$109→$119
Aug 12, 2026	BTIG	Jeet Mukherjee	PT Raise	Buy	$117→$133
Jul 22, 2026	HC Wainwright & Co.	Andres Y. Maldonado	PT Raise	Buy	$105→$125
Jun 30, 2026	BTIG	Jeet Mukherjee	PT Raise	Buy	$104→$117
Jun 29, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$105
Mar 30, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$100
Feb 23, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$104
Feb 2, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$104
Jan 29, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$100
Jan 14, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$104
Jan 9, 2026	Morgan Stanley	Maxwell Skor	Initiate	Overweight	$115
Nov 14, 2025	Raymond James	Chris Raymond	Downgrade	Strong Buy→Outperform	$142→$123
Nov 13, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$100
Nov 10, 2025	Leerink Partners	Joseph Schwartz	Initiate	Outperform	$115
Nov 9, 2025	Chardan Capital	Keay Nakae	PT Raise	Buy	$85→$100
Oct 13, 2025	Barclays	Etzer Darout	Initiate	Overweight	$125
Oct 6, 2025	Raymond James	Chris Raymond	PT Raise	Strong Buy	$80→$142
Oct 2, 2025	Oppenheimer	Andreas Argyrides	PT Raise	Outperform	$77→$115

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145

Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $128 to $145.

Benzinga Newsdesk

This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. STUB downgraded, MNPR neutral, BETR.

Avi Kapoor

PRO
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128

Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $125 to $128.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119

Cantor Fitzgerald analyst Kristen Kluska downgrades Monopar Therapeutics (NASDAQ:MNPR) from Overweight to Neutral and raises the price target from $109 to $119.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $117 to $133.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $105 to $125.

Benzinga Newsdesk

Monopar Therapeutics Inc

Monopar Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145

This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

PRO
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128

PRO
Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119

PRO
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133

PRO
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125

People Also Watch

People Also Watch

Monopar Therapeutics Inc

Monopar Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145

This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

PROBarclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128

PROCantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119

PROBTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133

PROHC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125

People Also Watch

People Also Watch

PRO
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145

PRO
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128

PRO
Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119

PRO
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133

PRO
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125